Matthias Holdhoff

2005–2025 年に発表

58
論文数
18,021
被引用数
32
h 指数
49
i10 指数

被引用数

Matthias Holdhoff の年別被引用数1993 年: 被引用 1 件2005 年: 被引用 2 件2006 年: 被引用 1 件2007 年: 被引用 2 件2008 年: 被引用 3 件2009 年: 被引用 6 件2010 年: 被引用 2 件2011 年: 被引用 7 件2012 年: 被引用 11 件2013 年: 被引用 25 件2014 年: 被引用 69 件2015 年: 被引用 156 件2016 年: 被引用 170 件2017 年: 被引用 237 件2018 年: 被引用 390 件2019 年: 被引用 1,024 件2020 年: 被引用 1,137 件2021 年: 被引用 1,136 件2022 年: 被引用 887 件2023 年: 被引用 662 件2024 年: 被引用 1,000 件2025 年: 被引用 477 件2026 年: 被引用 23 件1994〜2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,132 件、この内訳の 27.1%中国: 引用元論文 1,566 件、この内訳の 13.6%イタリア: 引用元論文 701 件、この内訳の 6.1%ドイツ: 引用元論文 655 件、この内訳の 5.7%イギリス: 引用元論文 605 件、この内訳の 5.2%フランス: 引用元論文 482 件、この内訳の 4.2%日本: 引用元論文 408 件、この内訳の 3.5%スペイン: 引用元論文 383 件、この内訳の 3.3%オランダ: 引用元論文 350 件、この内訳の 3%カナダ: 引用元論文 326 件、この内訳の 2.8%オーストラリア: 引用元論文 282 件、この内訳の 2.5%スイス: 引用元論文 230 件、この内訳の 2%
0%27.1%その他 21%

分野

  • Medicine60.7%
  • Biochemistry, Genetics and Molecular Biology32.3%
  • Immunology and Microbiology3.6%
  • Engineering1%
  • Materials Science0.8%
  • Neuroscience0.6%
  • その他1%

トピック

  • Cancer Genomics and Diagnostics11.2%
  • Cancer Immunotherapy and Biomarkers8.7%
  • Glioma Diagnosis and Treatment5%
  • Genetic factors in colorectal cancer4.8%
  • Pancreatic and Hepatic Oncology Research3.3%
  • Lung Cancer Treatments and Mutations3%
  • その他64%

共著者

全論文

検索で開く
  1. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shibin Zhou, Richard M. Goldberg, Deborah K. Armstrong, Katherine M. Bever, Amanda N. Fader, Janis M. Taube, Franck Housseau, David Spetzler, Nianqing Xiao, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, James R. Eshleman, Bert Vogelstein, Robert A. Anders, Luis A. Díaz - Science 2017 被引用: 6,766

  2. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore‐Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba‐Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian‐Li Wang, Jon Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein, Nickolas Papadopoulos, Luis A. Díaz - Science Translational Medicine 2014 被引用: 5,110

  3. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 719

  4. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stephanie E. Weiss, Patrick Y. Wen, Nicole E. Willmarth, Mary Anne Bergman, Susan Darlow - Journal of the National Comprehensive Cancer Network 2020 被引用: 564

  5. Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 307

  6. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nicole Shonka, Lode J. Swinnen, Stephanie E. Weiss, Patrick Y. Wen, Nicole E. Willmarth, Mary Anne Bergman, Susan Darlow - Journal of the National Comprehensive Cancer Network 2023 被引用: 223

  7. A multiprotein supercomplex controlling oncogenic signalling in lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa M. Rimsza, Fausto J. Rodríguez, Fayez Estephan, Matthias Holdhoff, Michael J. Kruhlak, Stephen M. Hewitt, Craig J. Thomas, Stefania Pittaluga, Thomas Oellerich, Louis M. Staudt - Nature 2018 被引用: 403

  8. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Chetan Bettegowda - National Academy of Sciences, Proceedings of the National Academy of Sciences 2015 被引用: 474

  9. Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β

    著者: , , , , , , , , , , , , - Molecular Therapy — Methods & Clinical Development 2022 被引用: 43

  10. NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christina Tsien, Stephanie E. Weiss, Patrick Y. Wen, Nicole E. Willmarth, Mary Anne Bergman, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2017 被引用: 231

  11. Identifying Recurrent Malignant Glioma after Treatment Using Amide Proton Transfer-Weighted MR Imaging: A Validation Study with Image-Guided Stereotactic Biopsy

    著者: , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 154

  12. First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma

    著者: , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2014 被引用: 232

  13. Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Oncotarget 2012 被引用: 582

  14. Central Nervous System Cancers, Version 1.2015

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frank D. Vrionis, Stephanie E. Weiss, Patrick Y. Wen, Nicole R. McMillian, Anita M. Engh - Journal of the National Comprehensive Cancer Network 2015 被引用: 178

  15. Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma

    著者: , , , , , , , , , , , , , , - Tomography 2022 被引用: 26

  16. LTBK-06. IMPACT OF VORASIDENIB TREATMENT ON MUTANT IDH1 OR IDH2 DIFFUSE GLIOMA TUMOR GROWTH RATE: RESULTS FROM THE RANDOMIZED, DOUBLE-BLIND, PHASE 3 INDIGO STUDY

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2023 被引用: 18

  17. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

    著者: , , , , , , , , , , , , , , , , , - Investigational New Drugs 2014 被引用: 105

  18. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 被引用: 67

  19. Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carl Koschmann, Natalya Smith, Karisa C. Schreck, Carlos A. Pardo, Michael Glantz, Matthias Holdhoff, Kenneth W. Kinzler, Nickolas Papadopoulos, Bert Vogelstein, Chetan Bettegowda - Cell Reports Medicine 2023 被引用: 18

  20. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas

    著者: , , , , , , - Journal of Neuro-Oncology 2019 被引用: 128

  21. MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Blood Advances 2019 被引用: 127

  22. Systemic use of tumor necrosis factor alpha as an anticancer agent

    著者: , , , - Oncotarget 2011 被引用: 177

  23. A multi-institutional pilot clinical trial of spectroscopic MRI-guided radiation dose escalation for newly diagnosed glioblastoma

    著者: , , , , , , , , , , , , , , , , , , - Neuro-Oncology Advances 2022 被引用: 41

  24. Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2020 被引用: 40